Drug Detail

Information about Perifosine

Generic Name	Perifosine
IND	KRX-0401
Brand Name (US)
Manufacturer	Keryx
Drug Type
Delivery
Approval Status	Phase 3
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block KIT Signal Path
Drug Category	AKT inhibitor

Periforsine is a novel oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity
KRX-0401 is in phase 3 trials (2011) for refractory colorectal cancer and multiple myeloma.